Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at surgery for people with kidney cancer that has spread (SURTIME; EORTC 30073)
This trial looked at the best time for people with kidney cancer that has spread to another part of the body to have surgery. It was supported by Cancer Research UK.
More about this trial
This trial was for people with a type of kidney cancer called clear cell kidney cancer. Doctors usually treat clear cell kidney cancer with surgery to remove the kidney (a nephrectomy), and sunitinib.
Researchers wanted to find out the best time to have surgery for this type of cancer. Some people in this trial had surgery first and then sunitinib. And some had sunitinib, then surgery, and then more sunitinib.
The main aim of this trial was to find out if it is better to have surgery or sunitinib first for clear cell kidney cancer that has spread.
Summary of results
- 50 people had surgery and then sunitinib
- 49 people had sunitinib, then surgery and then more sunitinib
- 46 people had surgery
- 40 people had sunitinib after their operation
- 48 people had some sunitinib to begin with
- 34 people had surgery
- 26 people had more sunitinib after their operation
- 21 out of 50 people (42%) who’d had surgery first
- 21 out of 49 people (43%) who’d had sunitinib first
- 35 out of 50 people (70%) who’d had surgery first
- 28 out of 49 people (57%) who’d had sunitinib first
- 14 out of 46 people (30%) who had surgery first
- 6 out of 34 people (18%) who had sunitinib first
- 18 out of 46 people (39%) who had surgery first
- 16 out of 34 people (47%) who had sunitinib first
How to join a clinical trial
Dr Axel Bex
Dr John Haanen
Cancer Research UK
European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Wales Cancer Trials Unit
This is Cancer Research UK trial number CRUK/10/050.